Program overview
Context
Indication: HER2 Positive
Mechanism: Unknown
Modality: Unknown
Sponsor: Sun Yat-sen University
Low Signal
Trastuzumab +Cetuximab β+Irinotecan
Trastuzumab +Cetuximab β+Irinotecan is flagged as low signal because public records show limited public risk signal. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 1/5
Recruitment burden: 1/5
Results availability: 0/5
Program risk: 1/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT07059338
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT07059338 | Low Signal (NOT_YET_RECRUITING) | stale_update_signal | Low Signal | rare_population_signal |